15 March 2019 | News
It is a generic version of BenzaClin® Gel, 1%|5%, of Valeant Bermuda
Glenmark Pharmaceuticals Inc., has been granted final approval by the United States Food & Drug Administration for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin® Gel, 1%|5%, of Valeant Bermuda.
According to IQVIATM sales data for the 12 month period ending January 2019, the BenzaClin® Gel, 1%|5% market achieved annual sales of approximately $99.4 million.
Glenmark’s current portfolio consists of 151 products authorized for distribution in the U.S. marketplace and 53 ANDA’s pending approval with the U.S. FDA.